![Nkarta, Inc. logo](/logos/NKTX.webp)
Nkarta, Inc.
NASDAQ:NKTX
Overview | Financials
Company Name | Nkarta, Inc. |
Symbol | NKTX |
Currency | USD |
Price | 5.32 |
Market Cap | 375,372,816 |
Dividend Yield | 0% |
52-week-range | 1.28 - 16.24 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Paul J. Hastings |
Website | https://www.nkartatx.com |
An error occurred while fetching data.
About Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD